Moderna, Inc. (MRNA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 143.38 |
| Open | 143.07 |
| Bid | 135.45 x 1100 |
| Ask | 136.00 x 1000 |
| Day's Range | 131.39 - 144.77 |
| 52 Week Range | 119.01 - 497.49 |
| Volume | |
| Avg. Volume | 7,157,155 |
| Market Cap | 55.243B |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | 8.16 |
| EPS (TTM) | 16.69 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 230.27 |
- Motley Fool
Better Buy: Moderna or Novavax?
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) are no longer big winners for investors. Let's first address the uncertainties for Moderna. There are questions about the high number of side effects of its experimental influenza vaccine.
- Motley Fool
Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
- Motley Fool
Here's How Moderna Could Top $450 Again
Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.
